Merck's Priority Review Cancer Drug Adds To Undervalued Growth Story [Yahoo! Finance]
DAIICHI SANKYO S/ADR (DSNKY)
NASDAQ:AMEX Investor Relations:
daiichisankyo.com/media_investors/investor_relations/index.html
Company Research
Source: Yahoo! Finance
U.S. FDA accepts and grants Priority Review for the Biologics License Application for ifinatamab deruxtecan. The application covers treatment of adult patients with extensive stage small cell lung cancer who have received at least one prior systemic therapy. If approved, ifinatamab deruxtecan could become the first B7-H3 directed therapy in this setting. The therapy is being co-developed by Merck (NYSE:MRK) and Daiichi Sankyo. For investors tracking NYSE:MRK, this Priority Review highlights an expansion effort beyond the company's existing oncology portfolio into small cell lung cancer, where treatment options remain limited. The product is an antibody drug conjugate targeting B7-H3, a different approach from many current therapies and one that fits with broader interest in targeted biologics across oncology. The FDA's decision to grant Priority Review shortens the review clock, which can bring regulatory clarity sooner than a standard review. For those following Merck, thi
Show less
Read more
Impact Snapshot
Event Time:
DSNKY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
DSNKY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
DSNKY alerts
High impacting DAIICHI SANKYO S/ADR news events
Weekly update
A roundup of the hottest topics
DSNKY
News
- Daiichi Sankyo and Interna partner for MNM-targeted delivery solutions [Yahoo! Finance]Yahoo! Finance
- Interna Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance MNM-Based Targeted Delivery Technologies [Yahoo! Finance]Yahoo! Finance
- Interna Therapeutics Announces Research Collaboration with Daiichi Sankyo to Advance MNM-Based Targeted Delivery TechnologiesPR Newswire
- Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase [Yahoo! Finance]Yahoo! Finance
- Wayfinder Biosciences Advances Collaboration with Daiichi Sankyo on Key Neurodegeneration Target to Second Phase [TheStreet.com]TheStreet.com